SCHEMBL10693025

SCHEMBL10693025

O=C1c2ccccc2C(=O)c2c(O)c3c(c(O)c21)CCCC3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
MAPT P10636 5/20 0.53
MAOA P21397 5/20 0.53
DAPK1 P53355 3/20 0.53
HPGD P15428 3/20 0.53
ALDH1A1 P00352 3/20 0.53
MAPK1 P28482 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
KDM4E B2RXH2 2/20 0.53
CYP3A4 P08684 2/20 0.53
ALOX15 P16050 2/20 0.53
ALOX12 P18054 2/20 0.53
RECQL P46063 2/20 0.53
CYP1B1 Q16678 2/20 0.53
HSD17B10 Q99714 2/20 0.53
TTR P02766 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
CYP1A1 P04798 1/20 0.53
HSPD1 P10809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13154692 0.84 MAOA (0.63) MEN1KMT2AMAPTMAOAHPGD
SCHEMBL11134072 0.82 MAPT (0.47) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL899150 0.80 MEN1 (0.68) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL13452113 0.80 MAOA (0.41) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL31745135 0.78 MAPT (0.44) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL11291057 0.78 MAPT (0.44) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL10113945 0.78 EGFR (0.64) MEN1KMT2AMAPTMAOAALDH1A1
SCHEMBL8581315 0.76 MEN1 (0.63) MEN1KMT2AMAPTMAOADAPK1
SCHEMBL11490030 0.76 ALDH1A1 (0.46) MEN1KMT2AMAPTMAOAALDH1A1
SCHEMBL497005 0.74 MEN1 (0.61) MEN1KMT2AMAPTMAOADAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0007403-B1 5,12-DIHYDROXY-1,2,3,4,6,11-HEXAHYDRO-2,6,11-TRIOXONAPHTHACENES AND THEIR SYNTHESIS THE UNIVERSITY OF KANSAS (US) 1982-11-24 EP claimed
US-20110015137-A1 RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY TRUSTEES OF BOSTON UNIVERSITY (US) 2011-01-20 US disclosed
US-4739062-A REACTING AN AROMATIC COMPOUND WITH DICARBOXYLIC ACID COMPOUND USING METAL HALIDE CATALYST CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1988-04-19 US disclosed
EP-0107486-B1 AMINONAPHTHACENE DERIVATIVES AND THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015137-A1 RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY CGAS, RPIA, CLPP MEN1 2527/4885KMT2A 4242/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.